Today GRAIL announced that the U.S. Food and Drug Administration’s (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026 to review the Premarket Approval (PMA) application for the Galleri® multi-cancer early
Today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation to make GRAIL’s Galleri multi-cancer early detection (MCED) test available to Priority Health’s self-insured
Many cancers stay hidden until it is too late. When cancer is diagnosed after it has spread distantly, it is more difficult to treat and typically has worse outcomes.
Diagnosing cancer before Stage IV can make a meaningful difference. For a growing number of cancers, treatment
